“Building on the R&D expertise accumulated through years of developing quality-assured biologics at Samsung Bioepis, we will focus on securing next-generation biotechnology platforms that can drive sustainable growth for the new company beyond the biosimilar business,” said Peter Seongwon Hong, CEO of Epis NexLab. “Our long-term goal is to become a leading biotechnology company in next-generation therapeutic technologies and we will be relentless in our efforts to drive this growth, through innovative research and development and strategic investment.”

Epis NexLab

Established in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is committed to driving innovation through the development of next-generation biotechnology platforms. By transforming highly scalable peptide-related technologies into development platforms, Epis NexLab will focus on the discovery of innovative treatment modalities for the development
=*=*=*=*=*=
当前为第2/3页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页